ÐÂÎÅÖÐÐÄ
News Center
ÈéÏÙ°©1ÀàÐÂÒ©¿âĪÎ÷ÀûÉÏÊÐÉêÇë»ñÊÜÀí bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ÅܳöÁ¢Òì¡°¼ÓËÙÂÊ¡±
Ðû²¼Ê±¼ä£º2024-07-19
7ÔÂ18ÈÕ £¬£¬£¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾(1177.HK£©ÏÂÊôÆóÒµÕý´óÌìÇç×ÔÖ÷Ñз¢µÄ1ÀàÁ¢ÒìÒ©¿âĪÎ÷Àû½ºÄÒ£¨Culmerciclib £¬£¬£¬£¬£¬£¬TQB3616£©ÍŽá·úά˾ȺעÉäÒº£¨É̱êÃû£ºÇç¿ÉÒÀ£© £¬£¬£¬£¬£¬£¬ÒÑÏò¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©µÝ½»ÐÂÒ©ÉÏÊÐÉêÇë²¢»ñÊÜÀí £¬£¬£¬£¬£¬£¬ÓÃÓÚ¼ÈÍùÄÚÉø͸¾Öεļ¤ËØÊÜÌ壨HR£©ÑôÐÔ¡¢È˱íƤÉú³¤Òò×ÓÊÜÌå2£¨HER2£©ÒõÐÔ¾Ö²¿ÍíÆÚ»òתÒÆÐÔÈéÏÙ°©µÄÖÎÁÆ¡£¡£¡£¡£¡£¡£
ÈéÏÙ°©ÊÇÅ®ÐÔ×î³£¼ûµÄ¶ñÐÔÖ×ÁöÖ®Ò» £¬£¬£¬£¬£¬£¬¿âĪÎ÷ÀûÓÐÍû³ÉΪbevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ÔÚ¸ÃÁìÓòµÄÊ׸öÁ¢ÒìÒ©¡£¡£¡£¡£¡£¡£ÔÚÕâÒ»ÁìÓò £¬£¬£¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾»¹½á¹¹ÓÐHER2Ë«¿¹µÄADCÒ©ÎïTQB2102¡¢HER2Ë«¿¹Ò©ÎïTQB2930¡¢AKT¡¢SERCA¡¢PARP1¡¢ER PROTACµÈÁ¢ÒìÒ©¡£¡£¡£¡£¡£¡£
¿âĪÎ÷ÀûÊÇÒ»ÖÖÐÂÐÍÖÜÆÚÂÑ°×ÒÀÀµÐÔ¼¤Ã¸2¡¢4ºÍ6£¨CDK2/4/6£©ÒÖÖƼÁ £¬£¬£¬£¬£¬£¬¶ÔCDK2¡¢CDK4¡¢CDK6¼¤Ã¸Óвî±ðˮƽµÄÒÖÖÆЧ¹û £¬£¬£¬£¬£¬£¬²¢ÇÒ¶ÔCDK4¼¤Ã¸¾ßÓнÏÇ¿µÄÒÖÖÆÄÜÁ¦[1]¡£¡£¡£¡£¡£¡£Ñо¿Ð§¹ûÏÔʾ £¬£¬£¬£¬£¬£¬¿âĪÎ÷Àû¶ÔCDK2¾ßÓÐÒÖÖÆ×÷Óà £¬£¬£¬£¬£¬£¬ÆäÔöÇ¿µÄCDK2ºÍCDK4ÒÖÖÆ»îÐÔ¿ÉÄÜÓÐÖúÓÚÔÚÁÙ´²ÉÏսʤÏÖÔÚCDK4/6ÒÖÖƼÁµÄÄÍÒ©ÐÔÎÊÌâ[1]¡£¡£¡£¡£¡£¡£
ÈéÏÙ°©ÊÇÖйúÅ®ÐÔ×î³£¼ûµÄÊ®´ó¶ñÐÔÖ×ÁöÖз¢²¡ÂÊÅÅÔÚµÚ¶þλµÄ°©Ö¢ £¬£¬£¬£¬£¬£¬ÖйúÿÄêз¢²¡ÀýÊý´ï36Íò[2]¡£¡£¡£¡£¡£¡£½üÄêÀ´ £¬£¬£¬£¬£¬£¬ÈéÏÙ°©·¢²¡ÂʺÍéæÃüÂʾù³ÊÉÏÉýÇ÷ÊÆ £¬£¬£¬£¬£¬£¬ÆäÖÐ £¬£¬£¬£¬£¬£¬Ô¼60%-70%µÄÈéÏÙ°©»¼ÕßΪHRÑôÐÔ¡¢HER2ÒõÐÔ¡£¡£¡£¡£¡£¡£
bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ÔÚÅ®ÐÔ¿µ½¡ÁìÓòÒ»Á¬¼Ó´ó½á¹¹ £¬£¬£¬£¬£¬£¬ÒÑͶÈë30¶àÒÚÔª £¬£¬£¬£¬£¬£¬¿ª·¢10¶àÌõ¹ÜÏß £¬£¬£¬£¬£¬£¬Á¢ÒìÒ©Ñз¢ÉÏһֱȡµÃÍ»ÆÆ¡£¡£¡£¡£¡£¡£ÔÚÈéÏÙ°©ÁìÓò £¬£¬£¬£¬£¬£¬´Ë´Î»ñÊÜÀíµÄ¿âĪÎ÷Àû×÷Ϊһ¿îÐÂÐÍCDK2/4/6ÒÖÖƼÁ £¬£¬£¬£¬£¬£¬½«ÎªHR+/HER2-ÈéÏÙ°©»¼ÕßÌṩеÄÖÎÁÆÑ¡Ôñ£»£» £»£»£»£»HER2Ë«¿¹µÄADCÒ©ÎïTQB2102¡¢HER2Ë«¿¹Ò©ÎïTQB2930Ò²¶¼½«Â½Ðø½øÈëÒªº¦×¢²áÁÙ´²ÊÔÑé¡£¡£¡£¡£¡£¡£Ëæ×ŶàÏîÔÚÑÐÁ¢ÒìÏîĿ½Ðø½øÈëÊÕ»ñÆÚ £¬£¬£¬£¬£¬£¬¹«Ë¾ÓÐÍûΪ¸ü¶àÅ®ÐÔ»¼ÕßÌṩԽ·¢¸»ºñµÄÖÎÁÆÑ¡Ôñ¡£¡£¡£¡£¡£¡£
³ýÉÏÊöÁ¢ÒìÒ©Íâ £¬£¬£¬£¬£¬£¬¹«Ë¾ÔÚÈéÏÙ°©ÖÎÁÆÁìÓò»¹¿ª·¢Á˶àÖÖ·ÂÖÆÒ©ÓëÉúÎïÀàËÆÒ©¡£¡£¡£¡£¡£¡£·úά˾ȺעÉäÒº£¨É̱êÃû£ºÇç¿ÉÒÀ£©¡¢ÒÀάĪ˾Ƭ£¨É̱êÃû£ºÇçάʱ£©¡¢×¢ÉäÓÃÇúÍ×Öéµ¥¿¹£¨É̱êÃû£ºÈüÍ×£©µÈÖØ°õ²úÆ·ÒѾÉÏÊÐ £¬£¬£¬£¬£¬£¬ÆäÖÐ £¬£¬£¬£¬£¬£¬·úά˾ȺÓÚ2020Äê8Ô»ñÅúÉÏÊÐ £¬£¬£¬£¬£¬£¬Îªº£ÄÚÊ×·Â £¬£¬£¬£¬£¬£¬ÇÒ³ö¿ÚÎ÷Å·¡£¡£¡£¡£¡£¡£ÁíÍâ £¬£¬£¬£¬£¬£¬ÅÁÍ×Öéµ¥¿¹×¢ÉäÒºÕýÔÚCDEÉÏÊÐÊÖÒÕÉóÆÀÖС£¡£¡£¡£¡£¡£ÕâЩ×÷ΪHR+¡¢HER2+ÈéÏÙ°©ÖÎÁÆÒ©Æ· £¬£¬£¬£¬£¬£¬¿É¼õÇỼÕßµÄÓÃÒ©¼ç¸º £¬£¬£¬£¬£¬£¬´ó´óÌá¸ßÒ©Îï¿É¼°ÐÔ¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1. Xu Z, Liu Y, Song B, et al. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor. Bioorganic & Medicinal Chemistry Letters 2024; 107.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2024; 74(3): 229-63.
ÉùÃ÷£º
1. ±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷ £¬£¬£¬£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ £¬£¬£¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£
2. ±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£¡£
3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼ £¬£¬£¬£¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼ £¬£¬£¬£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢ £¬£¬£¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö £¬£¬£¬£¬£¬£¬°üÀ¨Óйء¾¿âĪÎ÷Àû½ºÄÒ£¨Culmerciclib £¬£¬£¬£¬£¬£¬TQB3616£©¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ £¬£¬£¬£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö £¬£¬£¬£¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû £¬£¬£¬£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ïì £¬£¬£¬£¬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦ £¬£¬£¬£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö £¬£¬£¬£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇó £¬£¬£¬£¬£¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£¡£